MeSH D018281 - cholangiocarcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Helsinn Healthcare | Infigratinib | Truseltiq | 2028-08-06 | 2021-05-28 | ||
| Incyte | Pemigatinib | Pemazyre | 2033-06-12 | 2020-04-17 | $79.259 M | Q4/23-Q3/24 |
| Servier | Ivosidenib | Tibsovo | 2023-05-04 |
Clinical Trials
Historical Success Rate
Phase 1
77%53/69
Phase 2
18%18/102
Phase 3
20%5/25
Approved: 3Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use